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S_m Epidemiological evidence suggests that alcohol intake, use of tobacco, ingestion of mycotoxins and
nitrosamines and nutritional deficiencies are high-risk factors for the development of oesophageal cancer.
Similarly, viral infections have been postulated to play a role in some tumours. However, the mokcular events
underlying the development of oesophageal carcnoma are poorly understood as yet. Loss of p53 tumour-
suppressor gene function has been found in different human maignances, and it can occur in a variety of
ways, including gene mutation and interaction with the E6 protein of oncogenic human papillomaviruses
(HPVs). Because the oesophageal mucosa is potentially exposed to mutagens and HPVs, we studied DNA
samples derived from nine HPV-positive squamous cell carcinomas and 12 HPV-negtive tumours. Exons 5-9
of the p53 gene containing phylogenetically conserved domains were examined using the polymerase chain
reaction-single-strand conformation polymorphism (PCR-SSCP) technique. HPV detection was done using
DNA in situ hybridisation with biotm-labelled HPV DNA probes. Mutations were detected in eight (38%) out
of the 21 cases. Tree mutations were found in exons 5/6, three in exon 7 and two in exon 8/9. Six (50%) of
the 12 HPV-neatie carcinomas showed p53 mutations. Two (22.2%) of the nine HPV-positive carcinomas
were found to contain p53 mutations as well; one contained HPV 16 DNA sequences and showed p53
mutation in exon 8/9, and the other was HPV 6/11 positive with the mutation in exon 5/6. Although
mutations were more common in HPV-negative tumours (50.0% vs 222%), the difference in p53 mutations in
HPV-positive and -negative tumours did not reach statistical signii (P = 0.1946). These data indicate that
inactivation of the p53 gene is a frequent event in oesophageal squamous cell carcinomas and such an
inactivation might be an important molecular pathway for the development of oesophageal cancer. The
findings of p53 mutations in HPV-positive oesophageal arciomas suggest that HPV and p53 mutation were
not mutually exchlsive events. The presence of frequent mutations of p53 gene in both HPV-positive and
-negative oesophagal arwcmomas suggests a dominant role of environmental carcnogens in oesophageal
carcinogenesis.
The p53 gene encompasses 16-20 kb of DNA on the short
arm of human chromosome 17 at position 17pl3.1 (Miller et
al., 1986). This gene is composed of 11 exons, and encodes a
375 amino acid nuclear phosphoprotein involved in the
regulation of cell proliferation (Lane, 1992; Vogelstein &
Kinzler, 1992). During the past few years, a substantial
amount ofevidence has been accumulated to suggest that the
loss of normal p53 function is associated with cell transfor-
mation in vitro and development of neoplasms in vivo (Holl-
stein et al., 1991a; Levine et al., 1991; Chang et al., 1993a,b).
Loss of normal p53 function can occur in a variety of
ways, including genetic changes in the p53 gene, formation of
protein complexes with viral oncoprotens and bindg to
cellular gene products (Levine, 1990, 1991; Hollstein et al.,
1991a; Frebourg & Friend, 1992; Chang et al., 1993a,b).
Point mutations within the coding sequences of the p53
gene, giving rise to an altered protein, are currently regarded
as the most frequent genetic changes in humnan cancer. Ap-
proximately halfofadult cancers ofthe colon, stomach, lung,
oesophagus, breast, liver, brain, reticuloendothelial tissues
and haeinatopoietic tissues contain the mutant p53 gene
(Hollstein et al., 1991a; Levine et al., 1991). More than 90%
of the substitution mutations reported so far in malignant
tumours are clustered between exons 5 and 8 and are mostly
localised in the evolutionarily conserved regions (Hollstein et
al., 1991a).
Loss of normal p53 function can be caused by infections
with certain tumour viruses (Levine, 1990). It has been dem-
onstrated that the SV40 large T antigen (Schmeig & Sim-
mons, 1988), the adenovirus EIB protein (Sarnow et al.,
1982) and papillomavirus E6 protein (Werness et al., 1990)
are able to bind to p53. The HPV E6 proteins induce an
increased rate of p53 degradation (Werness et al., 1990).
Human papillomavirus (HPV) infections have been reported
in a number of body sites, such as the anogenital tract, skin
and aerodigestive tract (Syrjanen et al., 1987). Strong evi-
dence has accumulated in the past few years implicating an
aetiological role for specific HPV types in the development of
precancerous lesions and squamous cell carcinomas. Such
HPV-associated malignancies include anogenital carcinomas,
skin carcinomas developing from epidermodysplasia ver-
ruciformis lesions in immunocompromised patients as well as
carcinomas arising in the upper aerodigestive tract (Syrjanen
et al., 1987; Howlely, 1991; zur Hausen, 1991). Tumours
resulting from this pathway usually contain only wild-type
p53. Notable examples include cervical carcinomas, in which
p53 mutations appear to be rare in HPV-associated tumours,
but common in malignancies not associated with HPV infec-
tion (Crook et al., 1991; Scheffner et al., 1991).
Oesophageal cancer is an interestng model to study the
mechanisms of p53-associated tumorigenesis. Oesophageal
mucosa is continuously exposed to environmental carcin-
ogens and chemical irritants, including tobacco and alcohol
as well as mycotoxins and nitrosamines (Chang et al., 1992a).
Some of them are known to eLicit DNA base substitutions
and cause gene mutations either in bacteria and mammalian
cells in vitro or in experimental animals in vivo, and therefore
may lead to p53 mutations as well (Harris, 1991; Hollstein et
al., 1991a). In alignment with these experimental data, a high
percentage of gene mutations, allelic losses and other genetic
abnormalities in multiple tumour-suppressor genes, such as
the p53, RB, APC, MCC and DCC genes, has been recently
reported in this malignancy (Hollstein et al., 1990, 1991b;
Bennett et al., 1991, 1992; Boynton et al., 1991; Casson et al.,
1991; Meltzer et al., 1991; Greenwald et al., 1992; Huang et
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al., 1993). On the other hand, the loss of p53 normal func-
tion may result from the binding to HPV E6 transforming
proteins. HPV involvement in benign and malignant oesoph-
ageal squamous cell lesions has been established by histo-
pathological assessment showing HPV-suggestive lesions,
immunohistochemical studies demonstrating HPV antigens,
as well as DNA hybridisation studies disclosing HPV DNA
sequences in these lesions (Winkler et al., 1985; Kulski et al.,
1986; Chang et al., 1990; Williamson et al., 1991; Bena-
mouzig et al., 1992; Chang et al., 1992b-t, Toh et al., 1992).
These data, being in alignment with the evidence on the
aetiological role of HPV in squamous cell carcinomas at
other mucosal sites, implicate HPV as a potential aetiological
agent in oesophageal carcinogenesis as well.
Accordingly, it is feasible to analyse the p53 status of
oesophageal carcinomas with or without HPV infection. This
assessment may contribute to a better understanding of the
aetiological contribution of various risk factors in oesopha-
geal carcinogenesis. In the present study, we applied the
polymerase chain reaction-single-strand conformation poly-
morphism (PCR-SSCP) technique, shown to be a rapid and
highly sensitive method of dectecting genetic aberrations, to




Twenty-one tumour specimens, derived from the same
number of patients undergoing oesophagectomy for an
invasive squamous cell carcinoma, were included in the pres-
ent study. Nine samples had previously been shown to con-
tain HPV DNA sequences in cancer cells, and 12 samples
were HPV negative. All specimens had been collected from
the high-incidence area for oesophageal cancer in Linxian, a
county in Henan province of North China, with age-adjusted
mortality rates of 161.33 10- for males and 102.88 10-1 for
females (Lu et al., 1985). Specimens were obtained prior to
any clinical therapy. All samples were fixed in neutral for-
malin and embedded in paraffin.
HPV DNA detection by in situ hybridisation (ISH)
Biopsies were first examined for the presence of HPV DNA
by screening ISH with a commercial kit (Biohit HPV Screen-
ing Kit, Biohit, Helsinki, Finland), according to the manu-
facturer's protocol. The HPV DNA-positive samples were
further analysed by HPV typing ISH using biotin-labelled
HPV DNA probes of HPV types 6/11, 16, 18, 30 and 53,
under high-stringency conditions (Tm-17). HPV typing ISH
was performed as described earlier with minor modifications
(Syrjanen et al., 1988). Briefly, 4pm-thick sections were cut
from each biopsy and mounted on microscopic slides
pretreated with 1% aminopropyltriethoxysilane (Sigma, St
Louis, MO, USA). Sections were deparaffinised in xylene,
rehydrated through graded ethanols and digested with pro-
teinase K. The specimens were hybridised in a mixture of
50% formamide, 2 x SSC, 400pgml-' herring sperm DNA,
10% dextran sulphate and L.0pgml-' of each biotinylated
HPV DNA probe. Hybridisation was carried out in a 55-C
incubation oven overnight. Post-hybridization washes con-
sisted of 2 x SSC, twice for 5 mm at room temperature;
0.2 x SSC/0.1% SDS once at 55sC for 5 min; followed by a
5 min wash in 2 x SSC at room temperature. The slides were
incubated with streptavidin-alkaline phosphatase complex,
and successively developed with nitroblue tetrazolium and
bromochloroindoxyl phosphate.
p53 mutations detected by PCR-SSCP
DNA preparation After identification of suitable invasive
tumours from haematoxylin and eosin (HE)-stained slides,
5 pLm serial sections were prepared and deparaffinised in
xylene and rehydrated through graded alcohols. Samples con-
taining representative areas of invasive tumours were marked
and accurately removed using a scalpel to scrape tissues from
each serial slide. Similarly, areas shown to be HPV positive
in the ISH slides were marked, and the corresponding regions
in the serial sections were dissected. This method ensured
that only the tissues ofinterest were removed. In all tumours,
over 90% of cells removed from each slide appeared his-
tologically malignant. For obtaining HPV-positive tumour
cells, the regions of HPV-positive areas, which constituted as
little as 10% of the entire section, were removed. Contamina-
tion with adjacent non-malignant cells as well as HPV-
negative tumour cells was thus largely avoided and this was
extremely important in improving the sensitivity and speci-
ficity of the point mutation assay.
The dissected tissues were placed into Eppendorf tubes and
lysed in IO0M Tris-HCI (pH 7.5), 0.1 M sodium chloride;
10mM EDTA, 0.5% SDS, and 0.5 mgml1 proteinase K at
37C for 24 h. The total cellular DNAs were extracted by
phenol-chloroform-isoamylalcohol extraction and precipi-
tated with ethanol. To avoid contamination, separate labor-
atory materials and pipetting devices were set aside to be
used exclusively for working with tissue dissection and DNA
preparation.
PCR-SSCP Exons 5-9 of the p53 gene were examined for
alterations in DNA sequence using PCR amplification from
the genomic DNA followed by SSCP analysis as descibed
previously (Orita et al., 1989). Briefly, exon-specific PCR
primers were chosen so as to include 20 base pairs of intron
both 5' and 3' to the exon of interest. The nucleotide
sequence ofthe p53 gene used was that reported by Buchman
et al. (1988). Oligodeoxynucleotide amplimers, complemen-
tary to the adjacent target sequences, were synthesised on a
DNA synthesiser (Gene Assembler Plus, Pharmacia LKB,
Uppsala, Sweden). Their sequences were as follows: 5'-
TTCCTCTTCCTGCAGTACTC-3' and 5'-AGTTGCAAA-
CCAGACCTCAG-3' (for exons 5 and 6), 5'-GTGTTGTCT-
CCTAGGTTGGC-3' and 5'-CAAGTGGCrCCTGACCTG-
GA-3' (for exon 7) and 5'-CCTATCCTGAGTAGTGGTAA-
3' and 5'-CCCAAGACTTAGTACCTGAA-3' (for exons 8
and 9).
An aliquot of 500-1,000 ng of genomic DNA was
amplified in a volume of 20p1 containing 50 mM magnesium
chloride 0.01% (w/v) gelatin, 1.25mM each of four dNTPs,
20 pmol of each primer, 0.25 units of Taq DNA polymerase
(Perkin Elmer Cetus, Norwalk, CT, USA) and 0.5p1 of
[a-xPJdCTP (>3,000 Ci mmol ', Amersham, Arlington, IL,
USA). To prevent evaporation and condensation, the reac-
tion mixture was overlaid with 501L1 of paraffin oil. Target
DNA was first denatured at 95-C for 5 min, and then 35
cycles of amplification were performed with the Perkin-Elmer
Cetus automated thermal cycler (Perkin-Elmer Cetus). Each
cycle involved heating at 95°C for 30 s (DNA denaturation),
followed by cooling at 55"C for 50 s (primer annealing), and
finally heating at 72'C for 1 min (extension). The last exten-
sion step was prolonged by an additional 10 min. The HeLa
cell line contining HPV 16 genome and wild-type p53 was
used as a control in some experiments.
The PCR products were diluted 50-fold with buffer con-
taining 0.1% SDS and 10mM EDTA, and subjected to an
SSCP analysis. A 2 1l aliquot of PCR products was mixed
with an equal volume of buffer containing 95% formamide,
20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene
cyanol, heated at 95'C for 10 min, quickly chilled on ice and
applied to a 6% polyacrylamide gel containing 5% glycerol
using 0.5 x TBE as running buffer. Electrophoresis was per-
formed by using a sequencing-type apparatus, with 30 x 40
cm plates and 0.4 mm spacers, at 20 W for up to 7 h under
cooling with a fan at 25'C. After brief fixation with 10%
methanol and 10% acetic acid, gels were dried (Bio-Rad 583
gel dryer) for 1 h, and autoradiography was performed by
exposure to Kodak X-Omat AR film with an intensifing
screen at room temperature for 24 h.348 F. CHANG et al.
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HPV DNA in oesophageal carcinomas
The characteristics of the patients are summarised in Table I.
Of the 21 carcinoma specimens examined, nine had prev-
iously been demonstrated to contain HPV DNA sequences
by DNA in situ hybridisation (ISH). Of these HPV-positive
carcinomas, six were further demonstrated to contain at least
one of HPV 6, 11, 16, 18 and 30; three were infected with
HPV 16, one with HPV 18 and one with HPV 6/11, and one
was doubly infected with HPV 6/11 and 30. Three cases
contained HPV DNA sequences other than types 6, 11, 16,
18 and 30. The results of the HPV screening and typing ISH
of these biopsies have been detailed elsewhere (Chang et al.,
1993c, 1993d).
The positive signals were exclusively confined to the nuclei
of cancer cells. Within the invasive carcinoma samples, the
pattern of HPV-positive signals was often variable, and in
most cases the highest signal intensity was present in areas
showing the highest degree of squamous cell differentiation.
p53 mutations in oesophageal carcinomas
To assess the state of the p53 gene in HPV-positive car-
cinomas, the HPV DNA-positive regions in the serial sections
were accurately marked and dissected from the adjacent
HPV-negative regions. Because the regions of HPV-positive
areas often constitute as little as 10% of the entire section,
the microdissection was extremely important in avoiding the
'contamination' with adjacent non-malignant cells and/or
HPV-negative tumour cells. This helps to improve the
specificity of the p53 point mutation assay in HPV-positive
tumour cells.
Cellular DNA extracted from the HPV-positive cancer
cells was used for p53 gene amplification. In addition, 12
oesophageal carcinomas remaining HPV negative were also
include in the study, of which four were well differentiated,
six moderately and two poorly differentiated squamous cell
carcinomas.
To analyse the p53 status in these tumours, we employed
the PCR-SSCP technique. The p53 exons previously shown
to have a high incidence of mutations were target sequences
and included exon 5 (codons 126-187), exon 6 (codons
188-224), exon 7 (codons 225-261), exon 8 (codons
262-290) and exon 9 (Hollstein et al., 1991a; Levine et al.,
1991; Chang et al., 1993a,b). The results ofthe SSCP analysis
are shown in Table I. Mutations of the gene were identified
in 8 (38%) of the 21 tumours; three mutations were found in
exons 5/6, three in exon 7 and two in exon 8/9. Two (22.2%)
of the nine HPV-positive carcinomas showed p53 mutation;
one contained HPV 16 DNA sequences and showed p53
mutation in exon 8/9, and the other was HPV 6/11 positive
with p53 mutation in exon 5/6. Although mutations were
more common in HPV-negative tumours (50.0% vs 22.2%),
the difference in p53 mutations in HPV-positive and
-negative tumours did not reach statistical sigificnce (P=
0.1946).
Figure 1 shows an example of a PCR-SSCP analysis of
p53 mutations from amplified exons 5-6, 7 and 8-9 in 12
carcinoma specimens. The migration pattern of the normal
p53 allele amplified from normal tissues showed wild-type
migration (lane 0). Electrophoretic mobility shift was detec-
ted in two tumours in exon 5-6 (lanes 6 and 8 in Figure la),
in three tumours in exon 7 (lanes 7, 9 and 11 in Figure Ib)
and in two tumours in exon 8-9 (lanes 3 and 4 in Figure Ic).
The weak normal bands detected in these lanes were
presumably due to the presence of either normal cells or
heterogeneities in the tumours themselves.
Mutations in the p53 gene represent a common genetic lesion
in various types of human malignancies (Hollstein et al.,
1991a; Levine et al., 1991; Chang et al., 1993a,b). Most p53
mutations discovered in human cancers are missens changes
which occur primarily in four of five highly conserved
regions, spanning from the fifth to the eighth exon (Hollstein
et al., 1991a; Levine et al., 1991). In the present study, we
apphed the PCR-SSCP technique, which has proved to be a
rapid and sensitive means for identifying DNA sequence
variations as small as a single base substitutions (Orita et al.,
1989; Hayashi, 1992). p53 gene mutations were detected in 8
of the 21 (38%) oesophageal carcinomas in exons 5-9. This
is consistent with other reports of 30-50% prevalence ofp53
mutations in oesophageal squamous cell carcinomas, adeno-
carcinomas and in cell lines derived from oesophageal
cancers (Bennett et al., 1991, 1992; Casson et al., 1991;
Hollstein et al., 1990, 1991b; Meltzer et al., 1991; Blount et
al., 1991; Wagata et al., 1991; Huang et al., 1992). These
data suggest that p53 mutations represent an important path-
way in oesophageal carcinogenesis.
Table I Occurrence of p53 mutations and HPV infections in oesophageal squamous cell carcinomas
HPV infection
Case p53 gene no. Age Sex Diagnosis Screen ISH Typing ISH status
1 62 M Well + HPV 16 Wild-type
2 54 M Moderate + HPV 16 Mutant (exon 819) 3 38 F Poor + HPV 16 Wild-type
4 58 M Poor + HPV 18 Wild-type 5 43 F Moderate + HPV 6/11' Mutant (exon 5/6) 6 64 F Well + HPV 6/11" +30 Wild-type
7 69 M Poor + HPV X Wild-type 8 54 M Well + HPV X Wild-type
9 60 F Moderate + HPV X Wild-type 10 46 M Well - - Wild-type 11 56 M Well - - Mutant (exon 5i6) 12 59 M Well - - Wild-type
13 60 M Well - - Mutant (exon 7)
14 54 F Moderate - - Mutant (exon 5/6) 15 68 M Moderate - - Wild-type
16 54 M Moderate - - Mutant (exon 7) 17 52 M Moderate - - Mutant (exon 7)
18 44 M Moderate - - Wild-type
19 53 F Moderate - - Wild-type 20 38 F Poor - - Mutant (exon 8/9) 21 61 M Poor - - Wild-type
'HPV 6 and 11 mixed probes were used in typing in situ hybridisation. ISH, in situ hybridisation; HPV X, HPV type(s) other than HPV 6, 11, 16, 18, 30 and 53.p53 AND HPV IN OESOPHAGEAL CARCINOMAS 349
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Fume 1 Results of the PCR-SSCP analyses of the p53 gene
status in oesophageal carcinomas. a, b and c show the results
from amplified exons 5-6, 7 and 8-9 respectively. Arrowheads
indicate normal alleles and arrowsindicate shifted bands. Lanes 0
represent the wild-type p53, which was amplified from HeLa
cells. Lanes 6 and 8 in a, lanes 7, 9 and in b and lanes 3 and 4
in c show electrophoretic mobility shifts. Electrophoresis was
carried out at 20W for 5 h in 6% non-denaturing polyacrylamide
gel with 5% glycerol under cooling with a fan at room
temperature.
Loss of normal p53 function could be induced in a variety
of ways, one of which is binding to HPV E6 oncoproteins,
leading to an increased rate of p53 degradation (Werness et
al., 1990; Howley, 1991). This has been demonstrated as an
important pathway in HPV-mediated cervical carcinogenesis
(Crook et al., 1991; Howley, 1991; Scheffner et al., 1991).
The presence of HPV DNA sequences in oesophageal
squamous cell carcinomas, demonstrated in the present and
previous studies (Kulski et al., 1986; Chang et al., 1990;
Williamson et al., 1991; Benamouzig et al., 1992; Chang et
al., 1992b; Toh et al., 1992), suggests that inactivation of the
wild-type p53 by HPV E6 expression may represent a distinct
pathway in oesophageal carcinogenesis as well.
An even more interesting observation in our study was the
discovery of frequent p53 mutations in HPV-positive oeso-
phageal carcinomas, indicating that HPV and p53 mutation
are not mutually exclusive events. This is in contrast to the
situation in cervical carcinomas, in which mutations of the
p53 gene appear to be rare in cases associated with HPV
infections, but common in malignancies devoid of HPV infec-
tion (Crook et al., 1991; Scheffner et al., 1991; Iwasaka et al.,
1993). In the present study, although p53 mutations were
more frequent in HPV-negative tumours (22.2% vs 50.0%),
there was no statistically significant difference between HPV-
positive and -negative carcinomas (P =0. 1946). This diver-
gence may be due to different aetiological contribution of
carcinogenic factors in pathogenesis of these two carcinomas.
As mentioned above, inactivation of p53 by binding to E6
oncoprotein and by missense mutations are two distinct path-
ways. The mechanism leading to loss of tumour-suppressor
activity by binding to the HPV E6 transforming proteins
differs considerably from that due to p53 gene mutations or
allelic losses. Tumours resulting from HPV infection and
consequently E6 expression may contain only wild-type p53
gene (Crook et al., 1991; Howley, 1991; Scheffner et al., 1991;
Iwasaka et al., 1993). On the other hand, mutations or allelic
losses in the p53 gene largely derive from exposure to
exogenous carcinogens (Harris, 1991; Hollstein et al., 1991a;
Chang et al., 1993ab). These two factors may act indepen-
dently on the cells, but may sometimes act on the same cell
and cooperate with each other. The presence of both HPV
DNA sequences and p53 mutations in the same tumours in
the present study provides direct evidence for such a coopera-
tion.
Although HPV infections have been closely associated with
the development of a primary cervical carcinomas, it seems
likely that the initial HPV-induced lesions represent a
premalignant stage and that additional initiating factors are
required for a fully malignant transformation (SyTjinen et
al., 1987; zur Hausen, 1991). This is also seen in HPV-
immortalised primary human epithelial cells which are
initially non-transformed but acquire a tumorigenic pheno-
type by subsequent infection with an activated ras oncogene
(DiPaolo et al., 1989; Hurlin et al., 1991) or treatment with a
very low amount of a carcinogenic agent, e.g. nitrosamines
(Garrett et al., 1993), benzo[ajpyrene and methanesulphonic
acid ethyl ester (Li et al., 1992). The results of the present
study provide direct evidence to support the hypothesis that
certain HPV genomes are essential but not sufficient for
progression to malignancies and that synergistic actions with
other carcinogenic agents are required (zur Hausen, 1991).
Exposure to environmental mutagens or carcinogens causes
mutation or loss of one wild-type allele of the p53 or RB
gene, leading to a reduced concentration of the wild-type
p53. Cells with this genetic damage may acquire a selective
growth advantage, but still show benign phenotype. If the
cells are simultaneously infected with HPV, the reduced level
of the wild-type p53 could certainly enhance the ability of
E6/E7 proteins to complex with all p53 or RB proteins.
However, in patients developing a tumour without HPV
infection, the remaining p53 allele must be inactivated
through either point mutations or allelic losses.
As compared with the epithelium of the uterine cervix, the
oesophageal mucosa is continuously exposed to higher levels
of a large number of environmental carcinogens (Chang et
al., 1992a), many of which are known to elicit DNA base
substitutions and cause gene mutations either in bacteria and
mammalian cells in vitro or in experimental animals in vivo
(Harris, 1991; Holstein et al., 1991a). These factors may act
synergistically with HPV, leading to the development of car-
cinomas. This is in agreement with the increasing number of
reports on the high percentage of the gene mutations or
allelic losses of p53, RB and other tumour-suppressor genes
in oesophageal carcinomas (Hollstein et al., 1990; Bennett et
al., 1991, 1992; Boynton et al., 1991; Casson et al., 1991,
Hollstein et al., 1991b; Meltzer et al., 1991; Greenwald et al.,
1992; Huang et al., 1992, 1993). Indeed, base substitutions
are particularly frequent (60%) in patients who are con-
sumers of both tobacco and alcoholic beverages (Hollstein et
al., 1991a), the two most widespread risk factors for
oesophageal cancer. The frequent mutations of the p53 gene
in both HPV-positive and -negative oesophageal carcinomas
indicate that exposure to environmental carcinogens repre-
sents the predominant aetiological factor in the development
of oesophageal cancer, and infection with HPV may be one
of the promoting agents in a multistep process of oesopha-
geal carcinogenesis.
In conclusion, this study confirms and extends previous
reports indicating an important role for p53 gene in
eosophageal carcinogenesis. In addition to the high frequency
of p53 mutations in HPV-negative oesophageal cancers,
genetic alterations in the p53 gene were also common in
HPV-positive carcinomas. This suggests anintriguing pos-
sibility that p53 mutations and HPV E6 oncoprotein may
cooperate in the pathogenesis of some oesophageal car-
cinomas.
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